SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

Aurinia Pharmaceuticals Inc.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

05156V102

(CUSIP Number)

February 14, 2015

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

Item 1.

(a) Name of Issuer

Aurinia Pharmaceuticals Inc. (the “Issuer”).

(b) Address of Issuer’s Principal Executive Offices:

#1203-4464 Markham Street, Victoria, British Columbia V8Z7X8, Canada.

Item 2.

(a) Name of Person Filing

Lumira Capital Investment Management Inc. (“Lumira Capital”)

Lumira Capital II, L.P. (“LCII”)

Lumira Capital GP, L.P. (“Lumira GP”)

Lumira GP Holdings Co. (“Lumira GP Holdings”)

Lumira GP Inc. (“Lumira GP Inc.”)

Lumira Capital II (International), L.P. (“LCII (Int)”)

Benjamin Rovinski (each a “Reporting Person” and together, the “Reporting Persons”).    

Lumira Capital’s principal business is serving as an investment adviser to certain affiliated funds, including LCII and LCII (Int).

Lumira GP’s principal business is serving as the sole general partner of each of LCII and LCII (Int).

Lumira GP Holdings’ principal business is serving as one of two general partners of Lumira GP.

Lumira GP Inc’ principal business is serving as one of two general partners of Lumira GP.

Dr. Rovinski is a director of the Issuer and a managing director of Lumira Capital.

(b) Address of Principal Business Office or, if none, Residence

The business address of each of the Reporting Persons is 141 Adelaide Street West, Suite 770, Toronto, Ontario, Canada M5H 3L5.

(c) Citizenship

Dr. Rovinski is a Canadian citizen. Each of the other Reporting Persons is organized under the laws of Canada.

(d) Title of Class of Securities

Common Shares, no par value (“Common Shares”).

(e) CUSIP Number

05156V102. 

(a) ☐  Broker or dealer registered under Section 15 of the Exchange Act;

(b) ☐  Bank as defined in Section 3(a)(6) of the Exchange Act;

(c) ☐  Insurance company as defined in Section 3(a)(19) of the Exchange Act;

(d) ☐  Investment company registered under Section 8 of the Investment Company Act;

(e) ☐  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f) ☐  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g) ☐  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

(i) ☐  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

(j) ☐  Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

The information required by Items 4(a)-(c) as of the date hereof is set forth in Rows (7)-(13) of the cover page for each Reporting Person. By virtue of the relationships described in Item 2(a) herein, each of Dr. Rovinski, Lumira Capital, Lumira GP, Lumira GP Inc. and Lumira GP Holdings may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Act) the Common Shares which each of LCII and LCII (Int) directly beneficially owns. Each of Dr. Rovinski, Lumira Capital, Lumira GP, Lumira GP Inc. and Lumira GP Holdings disclaims beneficial ownership of such Common Shares. As of the date hereof, Dr. Rovinski holds 38,901 options to acquire Common Shares of the Issuer that are exercisable within 60 days, of which LCII holds all pecuniary interest therein, and 3,595 options to acquire Common Shares of the Issuer that are exercisable within 60 days, of which LCII (Int) holds all pecuniary interest therein.

The Reporting Persons filing this Schedule 13G inadvertently failed to file a report when originally due, but made this corrective filing when the oversight was discovered. The Reporting Persons’ ownership of the Common Shares exceeded 5% of the class when the Reporting Persons acquired the shares; however, as a result of subsequent issuances of Common Shares by the Issuer, the ownership of the Reporting Persons was reduced and the Reporting Persons ceased to be beneficial owners of more than 5% of the Common Shares as of March 20, 2017. The ownership totals stated in Rows (7)-(13) of the cover page for each Reporting Person reflect the reduction in such security ownership of the Reporting Persons, and are current as of the date of this Schedule 13G. 

On September 20, 2013, Dr. Rovinski became a director of the Issuer. On September 20, 2013, LCII acquired 610,238 Common Shares of the Issuer and 305,119 warrants exercisable within 60 days of September 20, 2013, representing approximately 7.22% of the Common Shares of the Issuer outstanding as of that date. Such percentage was calculated based on (i) 12,373,589 Common Shares issued and outstanding as of September 20, 2013, as reported to the Reporting Person by the Issuer, plus (ii) 305,119 Common Shares issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of September 20, 2013.

On September 20, 2013, LCII (Int) acquired 56,428 Common Shares of the Issuer and 28,214 warrants exercisable within 60 days of September 20, 2013, representing approximately 0.68% of the Common Shares of the Issuer outstanding as of that date. Such percentage was calculated based on (i) 12,373,589 Common Shares issued and outstanding as of September 20, 2013, as reported to the Reporting Person by the Issuer, plus (ii) 28,214 Common Shares issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of September 20, 2013.

On February 14, 2014, LCII acquired 1,165,636 Common Shares of the Issuer and 291,409 warrants exercisable within 60 days of February 14, 2014. As of that date, LCII beneficially owned 2,390,709 Common Shares of the Issuer, consisting of (i) 1,775,874 Common Shares, (ii) 596,528 Common Shares that were issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of February 14, 2014, and (iii) 18,307 Common Shares that were issuable to Dr. Rovinski upon exercise of outstanding options that were exercisable within 60 days of February 14, 2014, of which LCII held all pecuniary interest therein, representing approximately 7.49% of the Common Shares of the Issuer outstanding as of that date. Such percentage was calculated based on (i) 31,294,500 Common Shares issued and outstanding as of February 14, 2014, as reported to the Reporting Person by the Issuer, plus (ii) 596,528 Common Shares issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of February 14, 2014, plus (iii) 18,307 Common Shares that were issuable to Dr. Rovinski upon the exercise of outstanding options that were exercisable within 60 days of February 14, 2014, of which LCII held all pecuniary interest therein.

On February 14, 2014, LCII (Int) acquired 107,785 Common Shares of the Issuer and 26,946 warrants exercisable within 60 days of February 14, 2014. As of that date, LCII (Int) beneficially owned 221,066 Common Shares of the Issuer, consisting of (i) 164,213 Common Shares, (ii) 55,160 Common Shares that were issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of February 14, 2014, and (iii) 1,693 Common Shares that were issuable to Dr. Rovinski upon exercise of outstanding options that were exercisable within 60 days of February 14, 2014, of which LCII held all pecuniary interest therein, representing approximately 0.71% of the Common Shares of the Issuer outstanding as of that date. Such percentage was calculated based on (i) 31,294,500 Common Shares issued and outstanding as of February 14, 2014, as reported to the Reporting Person by the Issuer, plus (ii) 55,160 Common Shares issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of February 14, 2014, plus (iii) 1,693 Common Shares that were issuable to Dr. Rovinski upon the exercise of outstanding options that were exercisable within 60 days of February 14, 2014, of which LCII held all pecuniary interest therein.

On September 16, 2016, LCII exercised 305,119 warrants of the Issuer. As of that date, LCII beneficially owned 2,399,863 Common Shares of the Issuer, consisting of (i) 2,080,993 Common Shares, (ii) 291,409 Common Shares that were issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of September 16, 2016, and (iii) 27,461 Common Shares that were issuable to Dr. Rovinski upon the exercise of outstanding options that were exercisable within 60 days of September 16, 2016, of which LCII held all pecuniary interest therein, representing approximately 6.14% of the Common Shares of the Issuer outstanding as of that date. Such percentage was calculated based on (i) 38,794,000 Common Shares issued and outstanding as of September 16, 2016, as reported to the Reporting Person by the Issuer, plus (ii) 291,409 Common Shares issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of September 16, 2016, plus (iii) ) 27,461 Common Shares that were issuable to Dr. Rovinski upon the exercise of outstanding options that were exercisable within 60 days of September 16, 2016, of which LCII held all pecuniary interest therein.

On September 16, 2016, LCII (Int) exercised 28,214 warrants of the Issuer. As of that date, LCII (Int) beneficially owned 221,912 Common Shares of the Issuer, consisting of (i) 192,427 Common Shares of the Issuer, (ii) 26,946 Common Shares of the Issuer that were issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of September 16, 2016, and (iii) 2,539 Common Shares that were issuable to Dr. Rovinski upon the exercise of outstanding options that were exercisable within 60 days of September 16, 2016, of which LCII (Int) held all pecuniary interest therein, representing approximately 0.57% of the Common Shares of the Issuer outstanding as of that date. Such percentage was calculated based on (i) 38,794,000 Common Shares issued and outstanding as of September 16, 2016, as reported to the Reporting Person by the Issuer, plus (ii) 26,946 Common Shares issuable to the Reporting Person upon the exercise of outstanding warrants that were exercisable within 60 days of September 16, 2016, plus (iii) 2,539 Common Shares that were issuable to Dr. Rovinski upon the exercise of outstanding options that were exercisable within 60 days of September 16, 2016, of which LCII (Int) held all pecuniary interest therein.

On March 20, 2017, LCII purchased 274,607 Common Shares of the Issuer. As of that date, LCII beneficially owned 2,685,910 Common Shares of the Issuer, consisting of (i) 2,355,600 Common Shares of the Issuer, (ii) 291,409 Common Shares of the Issuer issuable to the Reporting Person upon the exercise of outstanding warrants that are exercisable within 60 days of the date hereof, and (iii) 38,901 Common Shares that are issuable to Dr. Rovinski upon the exercise of outstanding options that are exercisable within 60 days of the date hereof, of which LCII holds all pecuniary interest therein, representing approximately 4.37% of the Common Shares of the Issuer outstanding as of that date. Such percentage was calculated based on (i) 61,094,000 Common Shares issued and outstanding as of March 20, 2017, as reported to the Reporting Person by the Issuer, plus (ii) 291,409 Common Shares issuable to the Reporting Person upon the exercise of outstanding warrants that are exercisable within 60 days of the date hereof, plus (iii) 38,901 Common Shares that are issuable to Dr. Rovinski upon the exercise of outstanding options that are exercisable within 60 days of the date hereof, of which LCII holds all pecuniary interest therein.

On March 20, 2017, LCII (Int) purchased 25,393 Common Shares of the Issuer. As of that date, LCII (Int) beneficially owned 248,361 Common Shares of the Issuer, consisting of (i) 217,820 Common Shares of the Issuer, (ii) 26,946 Common Shares of the Issuer issuable to the Reporting Person upon the exercise of outstanding warrants that are exercisable within 60 days of the date hereof, and (iii) 3,595 Common Shares that are issuable to Dr. Rovinski upon the exercise of outstanding options that are exercisable within 60 days of the date hereof, of which LCII (Int) holds all pecuniary interest therein, representing approximately 0.41% of the Common Shares of the Issuer outstanding as of that date. Such percentage was calculated based on (i) 61,094,000 Common Shares issued and outstanding as of March 20, 2017, as reported to the Reporting Person by the Issuer, plus (ii) 26,946 Common Shares issuable to the Reporting Person upon the exercise of outstanding warrants that are exercisable within 60 days of the date hereof, plus (iii) 3,595 Common Shares that are issuable to Dr. Rovinski upon the exercise of outstanding options that are exercisable within 60 days of the date hereof, of which LCII (Int) holds all pecuniary interest therein.

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

Not applicable. 

Not applicable.

See Exhibit B.

Not applicable.

Not applicable.

EXHIBITS

1. Joint Filing Agreement, dated the date hereof, between the Reporting Persons.

2. Item 8 Statement.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:  April 6, 2017